Evusheld may not prevent COVID-19 in immunocompromised individuals exposed to the XBB.1.5 omicron subvariant, because the treatment has failed to neutralize similar subvariants, the Food and Drug Administration announced Friday. While it awaits additional data to verify this, FDA recommends health care providers inform patients about this risk, and advise them to test for COVID-19 and seek medical attention if they develop symptoms. XBB.1.5 currently accounts for about 28% of SARS-CoV-2 variants circulating in the U.S.

In other news, the FDA Friday approved through its accelerated pathway a new treatment for Alzheimer’s disease (Leqembi), the second in a new category of Alzheimer’s medications that target the underlying disease process.

Related News Articles

Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…
News
To enjoy a healthy Thanksgiving with family and friends, get vaccinated against the flu and COVID-19. That’s the message of AHA’s latest United Against the Flu…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical…